0001209191-23-033738.txt : 20230602 0001209191-23-033738.hdr.sgml : 20230602 20230602162726 ACCESSION NUMBER: 0001209191-23-033738 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230601 FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Richard A CENTRAL INDEX KEY: 0001490283 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 23989233 MAIL ADDRESS: STREET 1: C/O SYROS PHARMACEUTICALS, INC. STREET 2: 620 MEMORIAL DRIVE SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-01 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001490283 Young Richard A C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 1 0 0 0 0 Common Stock 2023-06-01 4 A 0 4000 0.00 A 36171 D Stock Option (right to buy) 3.70 2023-06-01 4 A 0 6000 0.00 A 2033-05-31 Common Stock 6000 6000 D The amount of securities beneficially owned following the transaction reported in this Form 4 reflects the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. /s/ Todd Rosenthal, as attorney-in-fact 2023-06-02